PTGS2 and breast carcinoma: Another study (Rahme et al, 2005) on menopausal women showed a reduction in breast cancer risk (OR 0.81, 95% CI 0.68–0.97) for COX2 inhibitor use of 90 days or longer, however, with shorter exposure (average of eight prescriptions).